Pilatus Biosciences Inc. has obtained IND clearance from the FDA for PLT-012, a first-in-class anti-CD36 monoclonal antibody, for the treatment of solid tumors. Pilatus plans to initiate a first-in-human phase I trial with this metabolic checkpoint antibody in the first quarter of next year.
Nectin-4 is a cell-surface protein that is highly expressed in a variety of solid tumors, including bladder, head and neck, and certain aggressive breast cancers. Its low-level expression in some normal tissues creates a challenge for therapies, which can unintentionally damage healthy cells and trigger severe side effects.
Pancreatic cancer is a leading cause of cancer-related deaths worldwide and presents a 5-year survival rate of under 12%. Most patients are diagnosed at an advanced stage, with over half of them presenting with metastatic disease at diagnosis.
Antibodies targeting CD269 and GPRC5D have shown unprecedented clinical efficacy in the treatment of multiple myeloma (MM), but many patients still develop progressive disease. It was hypothesized that dual-targeting T-cell immunotherapies might improve the efficacy by addressing the difficulty of heterogenous target expression and preventing resistance development due to antigen escape.
Scientists at East China Normal University and East China University of Science & Technology have synthesized 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.
Chengdu Kangnuoxing Biopharma Inc. and Keymed Biosciences Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising antibody or antigen binding fragments targeting cadherin-17 (CDH17) linked to a cytotoxic drug through a linker.
Astrazeneca plc has provided data for their CD22-targeting antibody-drug conjugate (ADC) AZD-4512 under development for the treatment of B-cell malignancies, which still have significant rates of disease resistance and relapse, as well as treatment-related toxicities.
Chengdu Kangnuoxing Biopharma Inc. and Keymed Biosciences Co. Ltd. have identified antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates consisting of antibodies covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Molecules that specifically bind to tumor-associated antigens (TAAs) are crucial for the diagnosis and therapy of cancer. In a recent publication in Molecular Therapy: Oncology, researchers from Université de Nantes presented a novel tailored-made affitin for targeting human mesothelin (hMSLN), which is a TAA overexpressed in many solid cancers and targeted by several experimental drugs.
RSS
